Separate clinical trials on two serious eye diseases, one set focused on advanced age-related macular degeneration and the other on central retinal vein occlusion, are reporting positive results for the drug VEGF Trap-Eye, Together, the two retinal diseases affect more than two million patients in the United States and more than 34 million worldwide. New results from these phase-3 clinical trials...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to New Drug is Effective against Potentially Blinding Retinal Diseases
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account
account